Desmoid Tumors Industry Outlook 2025-2029: Market Set to Cross $4.13 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Desmoid Tumors Market Size By 2025?
The market size for desmoid tumors has seen substantial growth of late. The predicted growth is from $2.97 billion in 2024 to $3.18 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.3%. The expansion in the historic period is due to advances in medical imaging, genetic studies and comprehension, surgical breakthroughs, as well as amplified awareness, education, and patient advocacy.

How Big Is the Desmoid Tumors Market Size Expected to Grow by 2029?
The market size for desmoid tumors is projected to experience robust growth in the coming years. The market is anticipated to reach $4.13 billion by 2029, with a compound annual growth rate (CAGR) of 6.8%. The increase in the prediction period can be credited to factors such as focused therapies, bespoke medication, broadened international collaborations, authoritative endorsements for innovative therapies, and patient-focused strategies. Predominant trends throughout this forecast period comprise progress in treatment methodologies, precision medicine, biomarker exploration, clinical investigation and research projects, multidisciplinary therapeutic squads, and patient support and advocacy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Which Key Market Drivers Powering Desmoid Tumors Market Expansion and Growth?
The expanding incidence of cancer is anticipated to bolster the growth of the desmoid tumor market in the future. Cancer is a term that encompasses a variety of ailments characterized by abnormal cell growth and proliferation in the body. These rogue cells can invade and damage surrounding tissue and organs. The escalating count of cancer instances around the globe has intensified the need for more advanced and potent chemotherapeutic drugs, which has a positive impact on the desmoid tumor market. For example, the National Cancer Institute, a federally-funded US agency, reported in May 2024 that they expect 2,001,140 new cancer diagnoses and 611,720 cancer-related fatalities in the U.S. in 2024. In 2022, nearly 20 million new cases and 9.7 million cancer-related deaths were reported globally. It is anticipated by 2040, the annual count of new cancer cases will reach 29.9 million, and cancer-related deaths will total 15.3 million. Hence, the escalating number of cancer cases is fueling the growth of the desmoid tumor market. The growth of the desmoid tumor market is expected to be fuelled by increasing government fund allocation towards research and development. Government funding, which is the monetary contribution made by the government for a specific cause, plays an instrumental role in enhancing tumor research and treatment. It provides crucial financial assistance for scientific investigations, medical facilities, and access to care, ameliorating cancer prevention, detection, and patient outcomes. For example, in September 2023, the National Cancer Institute, a US government entity, received a budget of $7.3 billion for the Cancer Moonshot from the US Congress for the fiscal year 2023 which represented a rise of $408 million from 2022. Consequently, the growth in government investments for research and development is fuelling the desmoid tumor market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Desmoid Tumors Market?
Prominent corporations in the desmoid tumors market are pioneering groundbreaking drugs like nirogacestat to enhance their service to existing clients. This medication is an oral, small-molecule gamma-secretase inhibitor. In February 2023, for example, SpringWorks Therapeutics Inc., a clinical-stage biopharmaceutical firm based in the US, received acceptance and priority review from the U.S. Food and Drug Administration (FDA) for their nirogacestat new drug application (NDA) for adults with desmoid tumors. Supposedly, nirogacestat functions by inhibiting the creation of notch proteins, which can cause tumor cell death. Desmoid tumors are noted for generating elevated levels of notch protein, which is believed to promote their growth. Moreover, nirogacestat presents patients with an alternative treatment that could potentially increase success rates.

What Are the Emerging Segments in the Desmoid Tumors Market?
The desmoid tumors market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users

Subsegments:
1) By Surgery: Wide Excision, Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Therapies
7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13228&type=smp

Who Are the Global Leaders in the Desmoid Tumors Market?
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

Which are the Top Profitable Regional Markets for the Desmoid Tumors Industry?
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13228

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.